CD44 but not CD24 expression is related to poor prognosis in non-cardia adenocarcinoma of the stomach

BMC Gastroenterology

Jing Jiang³  Yinping Wang²  Hongxi Ma²  Fei Kong³  Zhifang Jia³  MeiShan Jin²  Donghui Cao³  Xueyuan Cao¹ 

[1]Department of Gastric and Colorectal Surgery, First Hospital of Jilin University, Changchun, Jilin 130021, China

[2]Division of Pathology, First Hospital of Jilin University, Changchun, Jilin 130021, China

[3]Division of Clinical Epidemiology, First Hospital of Jilin University, Changchun, Jilin 130021, China

关键词: Helicobacter pylori;    Expression;    Gastric cancer;    Prognosis;    CD24;    CD44;   

Others  :  1121822
DOI  :  10.1186/1471-230X-14-157

 received in 2014-01-31, accepted in 2014-09-09,  发布年份 2014

【 摘 要 】

Background

Recent studies have focused on the diagnostic and prognostic significance of CD24 and CD44 expression in human cancers. This study aimed to explore changes in CD44 and CD24 expression levels in patients with gastric cancer and to assess their prognostic values.

Methods

CD44 and CD24 expression levels were investigated immunohistochemically in tumor samples from 290 patients with non-cardia gastric adenocarcinoma, of whom 77 had paired adjacent normal gastric mucosa. CD24 and CD44 mRNA levels were determined by quantitative polymerase chain reaction in 34 patients. Serum anti-Helicobacter pylori IgG was detected by enzyme-linked immunosorbent assay. Relationships between CD44 and CD24 protein expression levels and tumor parameters were analyzed and their prognostic values were evaluated by Cox proportional hazards models.

Results

CD24 and CD44 expression levels were significantly higher in patients with gastric cancer compared with those in paired controls (45.5% vs. 0.0%, and 61.0% vs. 0.0%, P < 0.001). Among 290 patients, the overall survival rate was significantly higher in CD44(−) compared with CD44(+) patients (log-rank test, P = 0.035). However, there was no significant correlation between CD24 expression and overall survival time (log-rank test, P = 0.115). Multivariate regression analysis indicated that positive CD44 expression (P = 0.029), TNM staging (P < 0.001), and lymphovascular invasion (P = 0.016), but not CD24 expression (P = 0.065), were independent prognostic factors in gastric cancer.

Conclusions

Individual expression of CD44 was associated with poor survival in patients with gastric carcinoma.

【 授权许可】

   
2014 Cao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3(11):e442.
• [2]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [3]Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S: Multivariate prognostic study on large gastric cancer. J Surg Oncol 2007, 96(1):14-18.
• [4]Sasako M, Inoue M, Lin JT, Khor C, Yang HK, Ohtsu A: Gastric cancer working group report. Jpn J Clin Oncol 2010, 40(Suppl 1):i28-i37.
• [5]Thomas S, Harding MA, Smith SC, Overdevest JB, Nitz MD, Frierson HF, Tomlins SA, Kristiansen G, Theodorescu D: CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res 2012, 72(21):5600-5612.
• [6]Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, Sima HR, Esmaili-Shandiz E, Hosseinnezhad H, Taghizadeh-Kermani A, Moaven O, Bahrani M: Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol 2008, 14(41):6376-6381.
• [7]Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H: CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006, 8(5):R59. BioMed Central Full Text
• [8]Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, Mori M: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24(3):506-513.
• [9]Zhang C, Li C, He F, Cai Y, Yang H: Identification of CD44 + CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol 2011, 137(11):1679-1686.
• [10]Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G: Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005, 11(18):6574-6581.
• [11]Yong CS, Ou Yang CM, Chou YH, Liao CS, Lee CW, Lee CC: CD44/CD24 expression in recurrent gastric cancer: a retrospective analysis. BMC Gastroenterol 2012, 12:95. BioMed Central Full Text
• [12]Bessede E, Staedel C, Acuna Amador LA, Nguyen PH, Chambonnier L, Hatakeyama M, Belleannee G, Megraud F, Varon C: Helicobacter pylori generates cells with cancer stem cell properties via epithelial-mesenchymal transition-like changes. Oncogene 2014, 33(32):4123-4131.
• [13]Lauren P: The Two histological main types of gastric carcinoma: diffuse and So-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
• [14]Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO classification of tumors of the digestive system. 4th edition. Lyon: IARC Press; 2010.
• [15]Chen S, Hou JH, Feng XY, Zhang XS, Zhou ZW, Yun JP, Chen YB, Cai MY: Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. J Surg Oncol 2013, 107(8):799-806.
• [16]Cao XY, Jia ZF, Jin MS, Cao DH, Kong F, Suo J, Jiang J: Serum pepsinogen II is a better diagnostic marker in gastric cancer. World J Gastroenterol 2012, 18(48):7357-7361.
• [17]Darwish NS, Kim MA, Chang MS, Lee HS, Lee BL, Kim YI, Kim WH: Prognostic significance of CD24 expression in gastric carcinoma. Cancer Res Treat 2004, 36(5):298-302.
• [18]Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, Theodorescu D: CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res 2011, 71(11):3802-3811.
• [19]Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, Sentani K, Oue N, Yasui W: Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol Int 2012, 62(2):112-119.
• [20]Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, Shi YH, Wang XY, Dai Z, Shi GM, Wu B, Wu LM, Yang GH, Zhang BH, Qin WX, Fan J: CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 2009, 15(17):5518-5527.
• [21]Kim K, Min HS, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Jang JJ, Ha SW: CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. World J Gastroenterol 2013, 19(9):1438-1443.
• [22]Takahashi M, Nakajima M, Ogata H, Domeki Y, Ohtsuka K, Ihara K, Kurayama E, Yamaguchi S, Sasaki K, Miyachi K, Kato H: CD24 expression is associated with progression of gastric cancer. Hepatogastroenterology 2013, 60(124):653-658.
• [23]Ozmen F, Ozmen MM, Ozdemir E, Moran M, Seckin S, Guc D, Karaagaoglu E, Kansu E: Relationship between LYVE-1, VEGFR-3 and CD44 gene expressions and lymphatic metastasis in gastric cancer. World J Gastroenterol 2011, 17(27):3220-3228.
• [24]Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S: CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002, 161(4):1215-1221.
• [25]Duckworth CA, Clyde D, Pritchard DM: CD24 is expressed in gastric parietal cells and regulates apoptosis and the response to Helicobacter felis infection in the murine stomach. Am J Physiol Gastrointest Liver Physiol 2012, 303(8):G915-G926.
• [26]Chen W, Zhang X, Chu C, Cheung WL, Ng L, Lam S, Chow A, Lau T, Chen M, Li Y, Nie Y, Wong BC, Pang R: Identification of CD44+ cancer stem cells in human gastric cancer. Hepatogastroenterology 2013, 60(124):949-954.
• [27]Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, Tanaka Y, Kurashige J, Miyamoto Y, Baba H: CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep 2013, 29(4):1570-1578.
• [28]Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, Watanabe M, Beppu T, Tamada M, Nagano O, Saya H, Baba H: CD44s regulates the TGF-beta-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res 2012, 72(13):3414-3423.
• [29]Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y, Wang TC: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27(5):1006-1020.
• [30]Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011, 17(2):211-215.
• [31]Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH: Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 2007, 14(10):2748-2758.
• [32]Ryu HS, do Park J, Kim HH, Kim WH, Lee HS: Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer. Hum Pathol 2012, 43(4):520-528.
• [33]Buck K, Hug S, Seibold P, Ferschke I, Altevogt P, Sohn C, Schneeweiss A, Burwinkel B, Jager D, Flesch-Janys D, Chang-Claude J, Marme F: CD24 polymorphisms in breast cancer: impact on prognosis and risk. Breast Cancer Res Treat 2013, 137(3):927-937.